US phase III trial of nabiximols (Sativex) for spasticity due to multiple sclerosis
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Nabiximols (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 05 Nov 2019 According to the GW Pharmaceuticals media release, the company expected to commence this study in Q1 2020.
- 26 Feb 2019 According to the GW Pharmaceuticals media release, this trial is expected to begin in Q4 2019.
- 07 May 2014 According to the GW Pharmaceuticals media release published on 7 May 2014, the US FDA granted Special Protocol Assessment.